Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 15, 2021

NewAmsterdam Pharma completes $196m Series A funding for phase 3 development programme

NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, announced completion of a $196M (€160M) Series A funding round.

NewAmsterdam Pharma completes $196m Series A funding for phase 3 development programme